1. Go AS, Mozaffarian D, Roger VL et al. AHA Statistical Update. Heart Disease and Stroke Statistics–2013 Update. A Report From the American Heart Association. Circulation 2013; 127: e6–e245.
2. Appel LJ, Frohlich ED, Hall JE et al. AHA Presidential Advisory. The Importance of Population-Wide Sodium Reduction as a Means to Prevent Cardiovascular Disease and Stroke. A Call to Action From the American Heart Association. Circulation 2011; 123: 1138–43.
3. Национальные рекомендации по диагностике и лечению артериальной гипертонии РМОАГ/ВНОК. Кардиоваскулярная терапия и профилактика (Прил. 2). 2008; 7 (6).
4. Intersalt Cooperative Research Group: Intersalt: an international study of electrolyte excretion and blood pressure. Results for 24 hour urinary sodium and potassium excretion. BMJ 1988; 297: 319–28.
5. Stamler J. The INTERSALT Study: background, methods, findings, and implications. Am J Clin Nutr 1997; 65: 626S–642S.
6. McCarron DA, Geerling JC, Kazacs AC et al. Can dietary sodium intake be modified by public policy? Clin J Am Soc Nephrol 2009; 4: 1878–82.
7. Carvalho JJ, Baruzzi RG, Howard PF et al. Blood pressure in four remote populations in the INTERSALT Study. Hypertension 1989; 14; 238–46.
8. Brown IJ, Tzoulaki I, Candeias V et al. Salt intakes around the world: implications for public health. Int J Epidemiol 2009; 38: 791–813.
9. Белоглазова И.П., Могутова П.А., Потешкина Н.Г. Потребление соли и ремоделирование сердца у больных артериальной гипертензией. Вестн. РГМУ. 2013; 1: 20–4.
10. Волков В.С., Поселюгина О.Б., Нилова С.А. Артериальная гипертония и потребление поваренной соли в России. Болезни сердца и сосудов. 2009; 9 (4): 16–8.
11. Elliott P, Stamler J, Nichols R et al. Intersalt revisited: further analyses of 24 hour sodium excretion and blood pressure within and across populations. BMJ 1996; 312: 1249–53.
12. Cook NR, Cutler JA, Obarzanek E et al. Long term effects of dietary sodium reduction on cardiovascular disease outcomes: observational follow-up of the trials of hypertension prevention (TOHP). BMJ 2007; 334: 885–93.
13. Meneton P, Jeunemaitre X, de Wardener HE et al. Links Between Dietary Salt Intake, Renal Salt Handling, Blood Pressure, and Cardiovascular Diseases. Physiol Rev 2005; 85: 679–715.
14. Safar ME, Temmar M, Kakou A et al. Sodium Intake and Vascular Stiffness in Hypertension. Hypertension 2009; 54: 203–9.
15. Institute of Medicine. Dietary reference intakes for water, potassium, sodium chloride, and sulfate. 1st ed. Washington, DC: The National Academies Press. 2004.
16. Jacobson MF. Salt The Forgotten Killer. Center for Science in the Public Interest. 2005.
17. He FJ, MacGregor GA. Salt intake and cardiovascular disease. Nephrol Dial Transplant 2008; 23 (11): 3382–5.
18. Farley T. Cut the salt. Get the facts: The National Salt Reduction Initiative. New York (NY): New York City Department of Mental Health and Hygiene. Available: www.nyc.gov/html/doh/downloads/pdf/cardio/cardio-salt-nsri-faq.pdf (accessed 2010 Dec. 2).
19. Law MR, Frost CD, Wald NJ. By how much does dietary salt reduction lower blood pressure? III: analysis of data from trials of salt reduction. BMJ 1991; 302: 819–24.
20. Hall JE. The Kidney, Hypertension, and Obesity. Hypertension 2003; 41: 625–33.
21. Obarzanek E, Proschan MA, Vollmer WM et al. Individual Blood Pressure Responses to Changes in Salt Intake: Results From the DASH-Sodium Trial. Hypertension 2003; 42: 459–67.
22. Adrogué HJ, Madias NE. Sodium and Potassium in the Pathogenesis of Hypertension. N Engl J Med 2007; 356: 1966–78.
23. Bidani AK, Griffin KA. Pathophysiology of Hypertensive Renal Damage: Implications for Therapy. Hypertension 2004; 44: 595–601.
24. Zandi-Nejad K, Luyckx VA, Brenner BM. Adult Hypertension and Kidney Disease. The Role of Fetal Programming. Hypertension 2006; 47: 502–8.
25. Kaplan NM. Kaplan’s Clinical Hypertension. Philadelphia/Baltimore/New York/London/Buenos Aires/Hong Kong/Sydney/Tokyo: Lippincott Williams & Wilkin, A Wolters Klummer Company USA, 2006.
26. Weinberger MH, Fineberg NS. Sodium and volume sensitivity of blood pressure. Age and pressure change over time. Hypertension 1991; 18; 67–71.
27. Fukuda M, Mizuno M, Yamanaka T et al. Pressure Dips During the Night Patients With Renal Dysfunction Require a Longer Duration Until Blood. Hypertension 2008; 52: 1155–60.
28. Chiolero A, Würzner G, Burnier M. Renal determinants of the salt sensitivity of blood pressure. Nephrol Dial Transplant 2001; 16: 452–8.
29. Pimenta E, Gaddam KK, Oparil S et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: results from a randomized trial. Hypertension 2009; 54: 475–81.
30. Frohlich ED. The Salt Conundrum A Hypothesis. Hypertension 2007; 50: 161–6.
31. Ritz E. The Kidney: Both Culprit and Victim. Hypertension 2009; 54; 25–6.
32. Gerber LM, Mann SJ, McDonald MV et al. Diuretic Use in Black Patients With Uncontrolled Hypertension. Am J Hypertens 2013; 26 (2): 174–9.
33. Sawicki PT, McGauran N. Have ALLHAT, ANBP2, ASCOT-BPLA, and So Forth Improved Our Knowledge About Better Hypertension Care? Hypertension 2006; 48; 1.
34. Jentzer JC, DeWald TA, Hernandez AF et al. Combination of Loop Diuretics With Thiazide-Type Diuretics in Heart Failure. JACC 2010; 56 (19): 1527–34.
35. Law MR, Morris JK, Wald NJ. Use of blood pressure lowering drugs in the epidemiological studies in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies. BMJ 2009; 338: b1665, doi:10.1136/bmj.b1665.
36. Weir MR, Agarwal R. Thiazide and Thiazide-Like Diuretics: Perspectives on Individualization of Drug and Dose Based on Therapeutic Index. Hypertension 2012; 59: 1089–90.
37. Messerli FH, Makani H, Benjo A et al. Antihypertensive Efficacy of Hydrochlorothiazide as Evaluated by Ambulatory Blood Pressure Monitoring. A Meta-Analysis of Randomized Trials. JACC 2011; 57 (5): 590–600.
38. Hawkins RG, Houston MC. Is Population-Wide Diuretic Use Directly Associated With the Incidence of End-Stage Renal Disease in the United States? : A Hypothesis. Am J Hypertens 2005; 18 (6): 744–9.
39. Hughes AD. How do thiazide and thiazide-like diuretics lower blood pressure? J Renin Angiotensin Aldosterone Syst 2004; 5: 155–60.
40. Strazzullo P, Galletti F, Barba G. Altered Renal Handling of Sodium in Human Hypertension: Short Review of the Evidence. Hypertension 2003; 41: 1000–5.
41. Ellison DH, Loffing J. Thiazide Effects and Adverse Effects: Insights From Molecular Genetics. Hypertension 2009; 54: 196–202.
42. Ganado P, Ruiz E, Del Rio M et al. Growth inhibitory activity of indapamide on vascular smooth muscle cells. Eur J of Pharm 2001; 428, Is.1 (28): 19–27.
43. Robinson DM, Wellington K. Indapamide Sustained Release. Drugs 2006; 66, Is. 2: 257–71.
44. London G, Schmieder R, Calvo C et al. Indapamide SR Versus Candesartan and Amlodipine in Hypertension: The X-CELLENT Study. Am J Hypertens 2006; 19 (1): 113–21.
45. Марченко И.В., Чаляби Т.А., Брель У.А. и др. Эффективность арифона ретард у больных гипертонической болезнью пожилого и очень пожилого возраста. Артериальная гипертензия. 2005; 2 (11): 98–102.
46. Puig JG, Marre MI, Kokot F et al. Efficacy of Indapamide SR Compared With Enalapril in Elderly Hypertensive Patients With Type 2 Diabetes. Am J Hypertens 2007; 20 (1): 90–7.
47. Shi-Wen Kuo, Pei-Dee, Yi-Jen Hung et al. Effect of indapamide SR in the treatment of hypertensive patients with type 2 diabetes. Am J Hypertens 2003; 16 (8): 623–8.
48. Beckett NS, Peters R, Fletcher AE et al for the HYVET Study Group. Treatment of hypertension in Patients 80 Years or Over. N Engl J Med 2008; 358 (18): 1887–98.
49. Williams B, Williams H, Northedge J et al. Newcastle Guideline Development and Research Unit. Updated by the National Clinical Guideline Centre and the British Hypertension Society. NICE clinical guideline 127. Hypertension: clinical management of primary hypertension in adults. Issue date: August 2011. www.nice.org.uk/guidance/CG127.

Н.Г.Потешкина

Кафедра общей терапии ФУВ ГБОУ ВПО РНИМУ им. Н.И.Пирогова Минздрава РФ